UFM
NRXP icon

Ursa Fund Management’s NRX Pharmaceuticals NRXP Stock Holding History

Ursa Fund Management’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,500
Closed -$37K – 34
2022
Q1 		$37K Buy
+1,500
New +$48.8K 0.01% 69

Other funds holding NRXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ursa Fund Management's NRXP Position: Q2 2022 in Review

Ursa Fund Management sold out of NRX Pharmaceuticals (NRXP) in Q2 2022, closing a stake of 1,500 shares — an estimated $37K sold.

Ursa Fund Management first reported a position in NRXP in Q1 2022 and held it in 1 quarter. The position peaked at $37K in Q1 2022. 37 funds tracked by Wall St. Rank hold NRXP as of Q2 2022.

  • Ursa Fund Management reported no remaining NRX Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Ursa Fund Management sold 1,500 NRX Pharmaceuticals shares in Q2 2022, an estimated $37K.
  • Ursa Fund Management first reported a position in NRX Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Ursa Fund Management's NRX Pharmaceuticals position peaked at $37K in Q1 2022.
  • 37 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2022.

Based on Ursa Fund Management's 13F filing for Q2 2022, filed 28 Jul 2022.